Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab + Anti-CD20 in R/R FL and DLBCL
NCT03401853Phase 2Terminated
- Sponsor
- University of Washington
- Start
- Mar 2018
- Primary completion
- Dec 2023
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of pembrolizumab in follicular lymphoma (FL), diffuse large B-cell lymphoma (DLBCL), sponsored by University of Washington. Started Mar 2018; status: terminated.
02
Drugs
03
Conditions
follicular lymphoma (FL)diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT03401853.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03401853.